Literature DB >> 15076241

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.

Hélène Peyrière1, Jacques Reynes, Isabelle Rouanet, Nathalie Daniel, Corinne Merle de Boever, Jean-Marc Mauboussin, Hélène Leray, Laurence Moachon, Denis Vincent, Dominique Salmon-Céron.   

Abstract

We describe 7 cases of renal tubular injury in HIV-infected patients receiving an antiretroviral regimen containing tenofovir. Our patients (5 women and 2 men) developed renal tubular dysfunction, with hypophosphatemia, normoglycemic glycosuria, proteinuria, and decrease of creatinine clearance. The first biologic signs of renal toxicity were observed after duration of tenofovir treatment from 5 weeks to 16 months, and they resolved less than 4 months after discontinuation of tenofovir. Six patients had a low body weight (<60 kg). Five patients received low doses of ritonavir, and 1 received didanosine. In 5 patients, the signs resolved with the discontinuation of only the tenofovir. A renal biopsy performed in 1 patient was consistent with tubulointerstitial injury. Proximal tubulopathy appears to be a rare adverse effect of long-term tenofovir therapy. In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076241     DOI: 10.1097/00126334-200403010-00007

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  78 in total

1.  Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.

Authors:  N Gara; X Zhao; M T Collins; W H Chong; D E Kleiner; T Jake Liang; M G Ghany; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2012-04-16       Impact factor: 8.171

2.  Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.

Authors:  Jessica A Brown; Lindsey R Pack; Jason D Fowler; Zucai Suo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 5.  Disease management--constructing optimal NRTI-based combinations: past, present, and future.

Authors:  Douglas T Dieterich
Journal:  MedGenMed       Date:  2006-01-19

Review 6.  [The side effects of antiretroviral therapy].

Authors:  M Hartmann
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

7.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

Review 8.  Sex differences in antiretroviral therapy-associated intolerance and adverse events.

Authors:  Rebecca Clark
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

9.  A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Authors:  Amber Dahlin; Matthias Wittwer; Melanie de la Cruz; Jonathan M Woo; Rujuta Bam; Valeska Scharen-Guivel; John Flaherty; Adrian S Ray; Tomas Cihlar; Samir K Gupta; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 10.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.